# Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma

> **NCT00896493** · PHASE2 · COMPLETED · sponsor: **Stanford University** · enrollment: 38 (actual)

## Conditions studied

- Mycoses
- Sezary Syndrome
- Lymphoma, T-Cell, Cutaneous
- Bone Marrow Transplant Failure
- Lymphoma, Non-Hodgkin
- Cutaneous T-cell Lymphoma

## Interventions

- **DRUG:** anti-thymocyte globulin
- **DRUG:** cyclosporine
- **RADIATION:** Lymphoid radiation

## Key facts

- **NCT ID:** NCT00896493
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-05
- **Primary completion:** 2021-11-06
- **Final completion:** 2022-12
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00896493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00896493, "Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00896493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*